Fig. 7
Tregs were required for promoting the M2-phenotype and phagocytosis by SIRPα-v Exos. A Representative flow cytometry images of CD4+ CD25+ cells in the ipsilateral STR around the hematoma on the 1st, 3rd, and 7th days post-ICH (n = 6/group). B Changes in the proportion of CD4+ CD25+ cells in the ipsilateral STR around the hematoma on the 1st, 3rd, and 7th days post-ICH (n = 6/group). * P < 0.05, ** P < 0.01, *** P < 0.001 vs. Sham group; # P < 0.05, ## P < 0.01 vs. Con group; ▲ P < 0.05, ▲▲ P < 0.01 vs. NC Exo group; ns, no significance. C Schematic illustration of the experimental design (combined application of Tregs and SIRPα-v Exos) in vitro. D The mRNA levels of CD206, TGFβ, IL-10, YM1/2, CD11b, CD16, CD32, and CD86 assessed by RT-qPCR after administration of Tregs or a combination of Tregs and SIRPα-v Exos (n = 3/group). E Representative immunofluorescence images of erythrocytes (red), Iba1 (green), and DAPI (blue) in primary microglia treated with or without Tregs and SIRPα-v Exos (scale bar1 = 25 μm, scale bar2 = 10 μm). The white arrows indicate microglia that phagocytosed erythrocytes. F Quantification analysis of the ratio of microglia phagocytosing erythrocytes in each field of view and erythrocytes phagocytosed per microglia 24 h after coculture with erythrocytes (n = 10/group). * P < 0.05, ** P < 0.01, *** P < 0.001 vs. Con group; # P < 0.05, ## P < 0.01 vs. SIRPα-v Exo group; ▲ P < 0.05, ▲▲ P < 0.01 vs. Treg group; ns, no significance. All the data are presented as the mean ± SD